UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 26, 2008

BIOPHAN TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-26057	82-0507874
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)

15 Schoen Place, Pittsford, New York 14534

(Address of principal executive offices) (Zip Code)

Copies to:

Gregory Sichenzia, Esq.

Andy Smith, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway

New York, New York 10006

Phone: (212) 930-9700

Fax: (212) 930-9725

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective as of March 31, 2009, Guenter Jaensch resigned as a member of the Board of Directors of Biophan Technologies, Inc., a Nevada corporation (the “Company”). No reason for the resignation was mentioned in the letter of resignation, a copy of which is filed herewith. However, the Company believes it was not due to any disagreement with the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

A copy of the notice of resignation submitted by Mr. Jaensch to the Company, dated as of March 22, 2009, is listed in the Index to Exhibits which immediately follows the signature page hereto. A copy of this current report was furnished to Mr. Jaensch prior to its filing.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIOPHAN TECHNOLOGIES, INC.

Dated: March 31, 2009	By:	/s/ John Lanzafame
		Name: John Lanzafame
		Title: Chief Executive Officer

99.1 Notice of Resignation of Guenter Jaensch, dated March 22, 2009 to Biophan Technologies, Inc.

BIOPHAN TECHNOLOGIES INC 8-K